Cover Image
市場調查報告書

先天性水皰症:開發中產品分析

Epidermolysis Bullosa - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213080
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
先天性水皰症:開發中產品分析 Epidermolysis Bullosa - Pipeline Review, H1 2017
出版日期: 2017年05月09日 內容資訊: 英文 101 Pages
簡介

先天性水皰症是先天水皰症障礙的一種,其特徵為對無意識外傷反應而形成水皰。主要的症狀有皮膚上的水皰形成、手指及指甲的畸形、損失、體內(喉嚨、食道、上部氣管、胃、腸、尿道等)形成水皰、手掌及腳掌皮膚的增厚化(角質增殖症)、頭皮出現水皰、疤痕化、毛髮脫落等。主要治療方法有抗生素及外科手術等。

本報告提供全球各國治療先天性水皰症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

先天性水皰症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

先天性水皰症:企業開發中的治療藥

先天性水皰症:大學/機關研究中的治療藥

先天性水皰症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

先天性水皰症:企業開發中的產品

先天性水皰症:大學/機關研究中的產品

先天性水皰症的治療藥開發企業

  • Birken AG
  • Fibrocell Science, Inc.
  • GlaxoSmithKline Plc
  • InMed Pharmaceuticals Inc.
  • Karus Therapeutics Limited
  • ProQR Therapeutics N.V.
  • RegeneRx Biopharmaceuticals, Inc.
  • Scioderm, Inc.
  • Stratatech Corporation
  • TWi Pharmaceuticals, Inc.
  • WAVE Life Sciences Ltd.

先天性水皰症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

先天性水皰症:最近的開發平台趨勢

先天性水皰症:暫停中的計劃

先天性水皰症:開發中止的產品

先天性水皰症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9232IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2017, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 2, 9 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Epidermolysis Bullosa - Overview
    • Epidermolysis Bullosa - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Epidermolysis Bullosa - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Epidermolysis Bullosa - Companies Involved in Therapeutics Development
    • Abeona Therapeutics Inc
    • Almirall SA
    • Amryt Pharma plc
    • Anterogen Co Ltd
    • Berg LLC
    • CSL Ltd
    • Exicure Inc
    • Fibrocell Science Inc
    • GlaxoSmithKline Plc
    • Immusoft Corp
    • InMed Pharmaceuticals Inc
    • Karus Therapeutics Ltd
    • Mesoblast Ltd
    • ProQR Therapeutics NV
    • RegeneRx Biopharmaceuticals Inc
    • Scioderm Inc
    • Stratatech Corp
    • TransDerm Inc
    • WAVE Life Sciences Ltd
  • Epidermolysis Bullosa - Drug Profiles
    • AC-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADP-31415 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • allantoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALLO-ASC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • birch bark extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Dermatology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FCX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICX-RHY - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INM-750 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KA-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QR-313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QRX-323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remestemcel-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGN-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ubidecarenone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Epidermolysis Bullosa - Dormant Projects
  • Epidermolysis Bullosa - Discontinued Products
  • Epidermolysis Bullosa - Product Development Milestones
    • Featured News & Press Releases
      • May 02, 2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
      • Apr 25, 2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
      • Apr 24, 2017: Amryt Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial for AP101 in EB
      • Apr 03, 2017: Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
      • Mar 28, 2017: Amryt Pharma: Phase 3 Clinical Trial for AP101 in EB
      • Mar 08, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
      • Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex
      • Mar 06, 2017: Amryt Pharma Announces AP101 trial discussions completed with FDA & EMA
      • Feb 27, 2017: RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
      • Feb 23, 2017: Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
      • Feb 07, 2017: Amryt Pharma: Grant of patent in Japan for lead drug candidate, AP101 (Episalvan) for Treatment of Epidermolysis Bullosa
      • Jan 18, 2017: Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa
      • Jan 05, 2017: Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
      • Dec 02, 2016: Amryt Pharma: €20m facility agreed with European Investment Bank
      • Nov 05, 2016: Abeona Therapeutics Honored with Partner in Progress Award from DEBRA of America
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Epidermolysis Bullosa, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H1 2017
  • Epidermolysis Bullosa - Pipeline by Almirall SA, H1 2017
  • Epidermolysis Bullosa - Pipeline by Amryt Pharma plc, H1 2017
  • Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, H1 2017
  • Epidermolysis Bullosa - Pipeline by Berg LLC, H1 2017
  • Epidermolysis Bullosa - Pipeline by CSL Ltd, H1 2017
  • Epidermolysis Bullosa - Pipeline by Exicure Inc, H1 2017
  • Epidermolysis Bullosa - Pipeline by Fibrocell Science Inc, H1 2017
  • Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Epidermolysis Bullosa - Pipeline by Immusoft Corp, H1 2017
  • Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, H1 2017
  • Epidermolysis Bullosa - Pipeline by Karus Therapeutics Ltd, H1 2017
  • Epidermolysis Bullosa - Pipeline by Mesoblast Ltd, H1 2017
  • Epidermolysis Bullosa - Pipeline by ProQR Therapeutics NV, H1 2017
  • Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
  • Epidermolysis Bullosa - Pipeline by Scioderm Inc, H1 2017
  • Epidermolysis Bullosa - Pipeline by Stratatech Corp, H1 2017
  • Epidermolysis Bullosa - Pipeline by TransDerm Inc, H1 2017
  • Epidermolysis Bullosa - Pipeline by WAVE Life Sciences Ltd, H1 2017
  • Epidermolysis Bullosa - Dormant Projects, H1 2017
  • Epidermolysis Bullosa - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Epidermolysis Bullosa, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top